| Molecular Cancer | |
| CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks | |
| Review | |
| Carsten Riether1  Michaela Medová2  Daniel M. Aebersold2  Yitzhak Zimmer2  Lusine Hovhannisyan3  | |
| [1] Department of Medical Oncology, Inselspital, University Hospital and University of Bern, 3010, Bern, Switzerland;Department of Radiation Oncology, Inselspital, Bern University Hospital, Freiburgstrasse 8, 3008, Bern, Switzerland;Department for Biomedical Research, Radiation Oncology, University of Bern, Murtenstrasse 35, 3008, Bern, Switzerland;Department of Radiation Oncology, Inselspital, Bern University Hospital, Freiburgstrasse 8, 3008, Bern, Switzerland;Department for Biomedical Research, Radiation Oncology, University of Bern, Murtenstrasse 35, 3008, Bern, Switzerland;Graduate School for Cellular and Biomedical Sciences, University of Bern, 3010, Bern, Switzerland; | |
| 关键词: Radiation therapy; CAR T cell therapy; Immunotherapy; | |
| DOI : 10.1186/s12943-023-01775-1 | |
| received in 2023-01-16, accepted in 2023-04-11, 发布年份 2023 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatment of solid tumors with CAR T cells is still a major challenge in the field and attempts to overcome these hurdles have not been successful yet. Radiation therapy is used for management of various malignancies for decades and its therapeutic role ranges from local therapy to a priming agent in cancer immunotherapy. Combinations of radiation with immune checkpoint inhibitors have already proven successful in clinical trials. Therefore, a combination of radiation therapy may have the potential to overcome the current limitations of CAR T cell therapy in solid tumor entities. So far, only limited research was conducted in the area of CAR T cells and radiation. In this review we will discuss the potential and risks of such a combination in the treatment of cancer patients.
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202308155523937ZK.pdf | 2221KB | ||
| 41116_2023_36_Article_IEq171.gif | 1KB | Image |
【 图 表 】
41116_2023_36_Article_IEq171.gif
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
- [60]
- [61]
- [62]
- [63]
- [64]
- [65]
- [66]
- [67]
- [68]
- [69]
- [70]
- [71]
- [72]
- [73]
- [74]
- [75]
- [76]
- [77]
- [78]
- [79]
- [80]
- [81]
- [82]
- [83]
- [84]
- [85]
- [86]
- [87]
- [88]
- [89]
- [90]
- [91]
- [92]
- [93]
- [94]
- [95]
- [96]
- [97]
- [98]
- [99]
- [100]
- [101]
- [102]
- [103]
- [104]
- [105]
- [106]
- [107]
- [108]
- [109]
- [110]
- [111]
- [112]
- [113]
- [114]
- [115]
- [116]
- [117]
- [118]
- [119]
- [120]
- [121]
- [122]
- [123]
- [124]
- [125]
- [126]
- [127]
- [128]
- [129]
- [130]
- [131]
- [132]
- [133]
- [134]
- [135]
- [136]
- [137]
- [138]
- [139]
- [140]
- [141]
- [142]
- [143]
- [144]
- [145]
- [146]
- [147]
- [148]
- [149]
- [150]
- [151]
- [152]
- [153]
- [154]
- [155]
- [156]
- [157]
- [158]
- [159]
- [160]
- [161]
- [162]
- [163]
- [164]
- [165]
- [166]
- [167]
- [168]
- [169]
- [170]
- [171]
- [172]
- [173]
- [174]
- [175]
- [176]
- [177]
- [178]
- [179]
- [180]
- [181]
- [182]
- [183]
- [184]
- [185]
- [186]
- [187]
- [188]
- [189]
- [190]
- [191]
- [192]
- [193]
- [194]
- [195]
- [196]
- [197]
- [198]
- [199]
- [200]
- [201]
- [202]
- [203]
- [204]
- [205]
- [206]
PDF